Affinity Proteomics

 

Recombinant antibody microarrays

Within Affinity Proteomics Group we develop, design and apply recombinant antibody microarrays for high-throughput (disease) proteomics, with a particular focus on oncoproteomics and autoimmunity.

We have adopted a cross-disciplinary technological approach to develop a state-of-the-art recombinant antibody microarray technology platform capable of handling most sample formats. The platform is continuously further developed and optimized, in order to provide us with cutting edge profiling tools. Consequently, the next generation of multiplexed analysis is now developed using NGS and a solution-based concept, denoted ProMIS.

Selected references:

  1. Carlsson A, Wingren C, Kristensson M, Rose C, Fernö M, Olsson H, Jernström H, Ek S, Gustavsson E, Ingvar C, Ohlsson M, Peterson C, Borrebaeck CAK (2011) Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci 108, 14252-14257.
  2. Wingren C, Sandström A, Segersvärd R, Carlsson A, Andersson R, Löhr M, Borrebaeck CAK (2012) Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res 72, 2481-2490.
  3. Borrebaeck CAK (2012) Viewpoint in Clinical Proteomics – When will proteomics deliver clinically useful information? Clin Proteomics 6, 343-345. Borrebaeck CAK (2017) Nat Rev Cancer 17(3):199-20
Page Manager: jana.hladilkova@immun.lth.se | 2021-12-09